Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2-Reference-Cited by-同舟云学术

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

Published:2015-03-02 Issue:7 Volume:62 Page:1171-1175
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Raetz Elizabeth A.¹,Cairo Mitchell S.²,Borowitz Michael J.³,Lu Xiaomin⁴,Devidas Meenakshi⁴,Reid Joel M.⁵,Goldenberg David M.⁶,Wegener William A.⁶,Zeng Hui⁴,Whitlock James A.⁷,Adamson Peter C.⁸,Hunger Stephen P.⁸,Carroll William L.⁹

Affiliation:

1. Department of Pediatrics and Huntsman Cancer Institute; University of Utah; Salt Lake City Utah

2. Department of Pediatrics; New York Medical College; New York New York

3. Department of Pathology; Johns Hopkins University; Baltimore Maryland

4. Department of Biostatistics; Colleges of Medicine, Public Health & Health Professions, University of Florida; Gainesville Florida

5. Department of Oncology; Mayo Clinic; Rochester Minnesota

6. Immunomedics, Inc.; Morris Plains New Jersey

7. Department of Pediatrics; University of Toronto and the Hospital for Sick Children; Toronto Ontario

8. Department of Pediatrics; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

9. NYU Perlmutter Cancer Center and Department of Pediatrics; NYU Langone Medical Center; New York New York

Funder

Children's Oncology Group

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.25454/fullpdf

Reference27 articles.

1. Factors influencing survival after relapse from acute lymphoblastic leukemia: A children's oncology group study;Nguyen;Leukemia,2008

2. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial;Parker;Lancet,2010

3. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90;Tallen;J Clin Oncol,2010

4. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A children's oncology group study[corrected];Raetz;J Clin Oncol,2008

5. The future role of monoclonal antibody therapy in childhood acute leukaemias;Barth;Br J Haematol,2012

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study;Blood Advances;2024-01-12

2. Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse;Journal of Clinical Oncology;2023-09-01

3. Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia;Molecular Therapy - Nucleic Acids;2023-09

4. Use of monoclonal antibodies in cancer immunotherapy: types and mechanisms of action;Boletín Médico del Hospital Infantil de México;2023-07-17

5. Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies;Cancers;2023-05-23